--- title: "RenovoRx | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 563 K" type: "News" locale: "en" url: "https://longbridge.com/en/news/286464035.md" datetime: "2026-05-14T20:31:37.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286464035.md) - [en](https://longbridge.com/en/news/286464035.md) - [zh-HK](https://longbridge.com/zh-HK/news/286464035.md) --- # RenovoRx | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 563 K Revenue: As of FY2026 Q1, the actual value is USD 563 K, beating the estimate of USD 463.25 K. EPS: As of FY2026 Q1, the actual value is USD -0.09, missing the estimate of USD -0.08. EBIT: As of FY2026 Q1, the actual value is USD -3.514 M. #### Segment Revenue RenovoRx, Inc. reported revenue of $563,000 for the three months ended March 31, 2026, which is a 136% increase compared to $197,000 for the same period in 2025 . This growth was attributed to the commercialization of RenovoCath and its adoption across U.S. cancer centers . #### Operational Metrics Gross profit for the three months ended March 31, 2026, was $479,000, an increase from $103,000 in the prior year period . The gross profit margin was 85.1% for Q1 2026, compared to 52.3% for Q1 2025 . Research and development expenses decreased to approximately $1.2 million for the first quarter of 2026 from approximately $1.6 million year-over-year, primarily due to higher receipts from the TIGeR-PaC clinical trial . Selling, general and administrative expenses increased to approximately $2.7 million for Q1 2026, compared to approximately $1.6 million for Q1 2025, reflecting the company’s commercial infrastructure strategy . Total operating expenses were $3.948 million for Q1 2026, compared to $3.213 million for Q1 2025 . Loss from operations was - $3.469 million for Q1 2026, compared to - $3.110 million for Q1 2025 . The net loss for the quarter ended March 31, 2026, was approximately - $3.5 million, compared to approximately - $2.4 million for the quarter ended March 31, 2025 . Operational highlights include an increase in active commercial cancer center customers from 5 at the beginning of 2025 to 16 as of May 6, 2026 . RenovoRx, Inc. also has a pipeline of 32 additional centers in various stages of evaluation, approval, and onboarding, and anticipates up to 15 TIGeR-PaC Phase III clinical trial sites transitioning to commercial use post-enrollment . The RenovoCath device has been used in 750 successful procedures since its FDA 510(k) clearance in 2014 . As of May 14, 2026, 106 out of 114 required patients (approximately 93%) had been randomized in the Phase III TIGeR-PaC trial, with full enrollment expected by the end of June 2026 . Final data from the TIGeR-PaC trial is anticipated in mid to late 2027 . #### Cash and Cash Equivalents Cash and cash equivalents were approximately $12.4 million as of March 31, 2026 . During the first quarter, RenovoRx, Inc. completed a private placement that generated approximately $10 million in gross proceeds . The company believes its current cash resources are sufficient to fund operations into at least the second half of 2027 . #### Unique Metrics As of March 31, 2026, common shares outstanding totaled 45.05 million . The initial total addressable market (TAM) for RenovoCath as a stand-alone device is estimated to represent an approximately $400 million peak annual U.S. sales opportunity, with long-term potential of several billion dollars as the platform expands into additional solid tumor indications . #### Outlook / Guidance RenovoRx, Inc. reiterated its full-year 2026 revenue guidance of $3 million to $4 million . The company expects continued revenue growth throughout 2026, supported by ongoing cancer center activations and the transition of TIGeR-PaC trial sites to commercial centers after full enrollment . Full enrollment for the TIGeR-PaC trial is projected to be completed by the end of June 2026 . ### Related Stocks - [RNXT.US](https://longbridge.com/en/quote/RNXT.US.md) ## Related News & Research - [RenovoRx Q1 revenue rises as number of active cancer centers increase](https://longbridge.com/en/news/286462396.md) - [RenovoRx Earnings Call Signals Commercial Inflection](https://longbridge.com/en/news/286979897.md) - [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [GDEV announces results for the first quarter of 2026 | GDEV Stock News](https://longbridge.com/en/news/286909689.md)